← ANALYST RATINGS · TIPRANKS
ADMA Biologics (ADMA): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy1 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $15.00, the highest $18.00, the lowest $12.00. The average is +40.4% from the last price of $10.68.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.00 → $12.50+13.6% | Buy | +17.0% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.00 → $12.50+13.6% | Buy | +17.0% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.50 → $12.00+14.3% | Buy | +12.4% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.50 → $12.00+14.3% | Buy | +12.4% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.00 → $12.50+13.6% | Buy | +17.0% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.50 → $13.00+13.0% | Buy | +21.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $18.00 | Buy | +68.5% | Reiterated | 06.08.26on TipRanks 07:06 | +8.8%next day −2.2% · 5 days −7.7% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $12.00 | Hold | +12.4% | Reiterated | 05.08.26on TipRanks Aug 6 09:15 | +4.1%next day +8.8% · 5 days +5.3% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $20.00 → $17.00−15.0% | Buy | +59.2% | Reiterated | 15.07.26on TipRanks 07:54 | −2.5%next day +2.0% · 5 days −2.5% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | $21.00 | Buy | +96.6% | Initiated | 10.06.26on TipRanks 07:36 | +6.0%next day −3.6% · 5 days −2.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ADMA Biologics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.67 at a price of $10.03 (+56.2%); now: $15.00 at $10.68 (+40.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 6 | 5 | 4 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.20 (from $0.19 to $0.20). Last quarter: $0.17.
Sales
Next quarter’s sales estimate — $138M (from $137M to $140M). Last quarter: $124M.
Best top-analyst consensus in the sector · Healthcare
About ADMA Biologics
- CEO: Adam S. Grossman
- Employees: 644
- 465 State Route 17, Ramsey, NJ, 07446, US
- www.admabiologics.com
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Data from the stock’s TipRanks forecast page, read 224 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗